Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
P/B ratio for Viracta Therapeutics, Inc. (VIRX)
P/B ratio as of 2023: 1.20
According to Viracta Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.20. At the end of 2022 the company had a P/B ratio of 0.90.
P/B ratio history for Viracta Therapeutics, Inc. from 2004 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.20 |
| 2022 | 0.90 |
| 2021 | 1.23 |
| 2020 | -0.01 |
| 2019 | 1.08 |
| 2018 | 3.75 |
| 2017 | 4.21 |
| 2016 | 2.71 |
| 2015 | 2.40 |
| 2014 | 38.93 |
| 2013 | -140.52 |
| 2012 | 59.34 |
| 2011 | 6.80 |
| 2010 | 6.44 |
| 2009 | 62.66 |
| 2008 | 5.95 |
| 2007 | 5.46 |
| 2006 | 7.75 |
| 2005 | 10.43 |
| 2004 | 2.89 |